{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:02:13Z","timestamp":1789239733348,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T00:00:00Z","timestamp":1563580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T00:00:00Z","timestamp":1563580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40261-019-00830-4","type":"journal-article","created":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T02:02:23Z","timestamp":1563588143000},"page":"1067-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson\u2019s Drug Discovery"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-6217","authenticated-orcid":false,"given":"M. Soledad","family":"Cepeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy R.","family":"Seabrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lovestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,20]]},"reference":[{"issue":"11","key":"830_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353.","journal-title":"Lancet Neurol"},{"issue":"3","key":"830_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3233\/JPD-150570","volume":"5","author":"D Stephenson","year":"2015","unstructured":"Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, et al. precompetitive data sharing as a catalyst to address unmet needs in Parkinson\u2019s disease. J Parkinsons Dis. 2015;5(3):581\u201394.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"830_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic. Mov Dis. 2018;33(5):684\u201396.","journal-title":"Mov Dis"},{"issue":"9","key":"830_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"153","author":"PE Stang","year":"2010","unstructured":"Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600\u20136.","journal-title":"Ann Intern Med"},{"key":"830_CR5","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574\u20138.","journal-title":"Stud Health Technol Inform"},{"issue":"6354","key":"830_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. \u03b22-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357(6354):891\u20138.","journal-title":"Science"},{"issue":"1","key":"830_CR7","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","volume":"9","author":"F Cheng","year":"2018","unstructured":"Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"830_CR8","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1007\/s40264-013-0101-3","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S95\u2013106.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"830_CR9","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1007\/s40264-013-0108-9","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143\u201358.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"830_CR10","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1007\/s40264-013-0110-2","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36(Suppl 1):S171\u201380.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"830_CR11","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1007\/s40264-013-0105-z","volume":"36","author":"D Madigan","year":"2013","unstructured":"Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73\u201382.","journal-title":"Drug Saf"},{"issue":"1","key":"830_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000365590","volume":"43","author":"DA Butt","year":"2014","unstructured":"Butt DA, Tu K, Young J, Green D, Wang M, Ivers N, et al. A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends. Neuroepidemiology. 2014;43(1):28\u201337.","journal-title":"Neuroepidemiology"},{"issue":"7414","key":"830_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"830_CR14","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.","journal-title":"BMJ"},{"issue":"4","key":"830_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/aje\/kwt010","volume":"178","author":"D Madigan","year":"2013","unstructured":"Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645\u201351.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"830_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles Nielsen","year":"2018","unstructured":"Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA. \u03b22-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84(5):683\u201393.","journal-title":"Ann Neurol"},{"issue":"3","key":"830_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jamia\/ocu023","volume":"22","author":"EA Voss","year":"2015","unstructured":"Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553\u201364.","journal-title":"J Am Med Inform Assoc"},{"key":"830_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-017-0090-8","volume":"6","author":"C Ma","year":"2017","unstructured":"Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Transl Neurodegener. 2017;6:18.","journal-title":"Transl Neurodegener"},{"key":"830_CR19","unstructured":"Kalia L, Yo R. \u03b22-Adrenoreceptor agonists and antagonists and Parkinson\u2019s disease. 2019. \nhttps:\/\/www.movementdisorders.org\/MDS\/Scientific-Issues-Committee-Blog\/B2-Adrenoceptor-agonists.htm\n\n. Accessed 01 Feb 2019."},{"issue":"5","key":"830_CR20","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1476-5381.2010.00754.x","volume":"160","author":"JG Baker","year":"2010","unstructured":"Baker JG. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010;160(5):1048\u201361.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"830_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00210-003-0860-y","volume":"369","author":"C Hoffmann","year":"2004","unstructured":"Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes\u2013characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(2):151\u20139.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"830_CR22","doi-asserted-by":"publisher","first-page":"e81802","DOI":"10.1371\/journal.pone.0081802","volume":"8","author":"P Sheng","year":"2013","unstructured":"Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8(12):e81802.","journal-title":"PLoS One"},{"issue":"Pt A","key":"830_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.brainres.2015.12.026","volume":"1640","author":"ND Osier","year":"2016","unstructured":"Osier ND, Dixon CE. Catecholaminergic based therapies for functional recovery after TBI. Brain Res. 2016;1640(Pt A):15\u201335.","journal-title":"Brain Res"},{"issue":"4","key":"830_CR24","first-page":"139","volume":"7","author":"J Wisor","year":"2013","unstructured":"Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;7(4):139.","journal-title":"Front Neurol"},{"issue":"29","key":"830_CR25","doi-asserted-by":"crossref","first-page":"47284","DOI":"10.18632\/oncotarget.17618","volume":"8","author":"QM Wang","year":"2017","unstructured":"Wang QM, Xu YY, Liu S, Ma ZG. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. Oncotarget. 2017;8(29):47284\u201395.","journal-title":"Oncotarget"},{"issue":"15 Suppl","key":"830_CR26","first-page":"P2.39","volume":"90","author":"T Simuni","year":"2018","unstructured":"Simuni T, Holloway R, Oakes D, Biglan K, Lungu C. A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson\u2019s disease (STEADY-PD III): baseline characteristics and study update [abstract no. P2.039]. Neurology. 2018;90(15 Suppl):P2.39.","journal-title":"Neurology"},{"key":"830_CR27","unstructured":"Bowser AD. Isradipine for Parkinson\u2019s disease fails in phase 3 study. AHS 2019 conference news. 2019. \nhttps:\/\/www.mdedge.com\/neurology\/article\/199907\/parkinsons-disease\/isradipine-parkinsons-disease-fails-phase-3-study\n\n. Accessed 07 Jun 2019."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00830-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00830-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00830-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T19:25:27Z","timestamp":1595100327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00830-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,20]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00830-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,20]]},"assertion":[{"value":"20 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Janssen Research & Development, LLC funded the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Soledad Cepeda, David M. Kern, Guy R. Seabrook, and Simon Lovestone are employees of Janssen Research & Development, LLC. Janssen Research & Development, LLC has an interest in Parkinson\u2019s disease.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The New England Institutional Review Board (NEIRB) determined that studies conducted with the Optum<sup>\u00ae<\/sup> database (NEIRB #12-286) or the MarketScan databases (NEIRB #12-284) do not qualify as human subjects research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}